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Gray matter lesionMyelin loss is a severe pathological hallmark common to a number of neurodegenerative diseases,
including multiple sclerosis (MS). Demyelination in the central nervous system appears in the form of
lesions affecting both white and gray matter structures. The functional consequences of demyelination
on neuronal network and brain function are not well understood. Current therapeutic strategies for ame-
liorating the course of such diseases usually focus on promoting remyelination, but the effectiveness of
these approaches strongly depends on the timing in relation to the disease state. In this study, we sought
to characterize the time course of sensory and behavioral alterations induced by de- and remyelination to
establish a rational for the use of remyelination strategies. By taking advantage of animal models of
general and focal demyelination, we tested the consequences of myelin loss on the functionality of the
auditory thalamocortical system: a well-studied neuronal network consisting of both white and gray
matter regions. We found that general demyelination was associated with a permanent loss of the tono-
topic cortical organization in vivo, and the inability to induce tone-frequency-dependent conditioned
behaviors, a status persisting after remyelination. Targeted, focal lysolecithin-induced lesions in the
white matter fiber tract, but not in the gray matter regions of cortex, were fully reversible at the morpho-
logical, functional and behavioral level. These findings indicate that remyelination of white and gray mat-
ter lesions have a different functional regeneration potential, with the white matter being able to regain
full functionality while cortical gray matter lesions suffer from permanently altered network function.
Therefore therapeutic interventions aiming for remyelination have to consider both region- and
time-dependent strategies.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Processes influencing axonal myelination, including myelin loss
and gain, are well known physiological events. Severe pathophys-
iological alterations of the degree of myelination are peculiar hall-
marks of a number of neurodegenerative diseases, includingmultiple sclerosis (MS; Meuth et al., 2010). In MS patients, inter-
mingled episodes of de- and remyelination are associated with
the occurrence of gray and white matter lesions in brain and spinal
cord. Furthermore, converging evidence relates the occurrence of
lesions to the onset or worsening of disease symptoms (Franklin
et al., 2012). Myelin plays multiple physiological roles and it is
intuitive that its loss may have severe consequences; after all,
myelin integrity is important for neuronal and axonal survival, as
well as faithful transmission of information in a given network of
the central nervous system (CNS; Yates, 2014; Nave and Werner,
2014). In line with white matter damage, MS patients often are
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2013) as indicated by delayed evoked auditory, sensory, motor and
visual potentials (Markianos et al., 2009; Matas et al., 2010; Niklas
et al., 2009).
Physicians and researchers are now developing new therapeutic
strategies to ameliorate disease symptoms by promoting remyeli-
nation. This attempt is fueled by recent evidence demonstrating
that myelin is required for learning motor tasks and similarly
how the acquisition of new information promotes myelin synthe-
sis, both in humans and rodents (Franklin and Gallo, 2014;
McKenzie et al., 2014). Indeed, this approach has already been
adopted in many clinical trials, but positive results have not been
observed in all patients (Bhatt et al., 2014). Therefore strategies
to identify eligible patients with highest possible benefit are
urgently needed. In this context, it is important to note that
numerous MS patients also report severe learning and cognitive
dysfunctions in addition to locomotor impairment (Hulst et al.,
2013; Manrique-Hoyos et al., 2012), and none of these symptoms
can be fully explained by massive or local myelin loss alone. New
techniques used for MS diagnosis point to many gray matter struc-
tures being severely damaged in MS patients (Hulst and Geurts,
2011). In particular, the thalamocortical system seems to be sus-
ceptible as cortical atrophy (Deppe et al., 2014; Minagar et al.,
2013) and thalamic lesions as well as lesion-independent degener-
ation are often observed very early in the disease course. In the
light of such evidence and the obvious complexity of MS
pathophysiology, the aim of our study was to investigate func-
tional consequences of various demyelination strategies and then
to allow endogenous remyelination. By taking into consideration
the diversity (whether white or gray matter) and the timing of
the lesions we tried to establish a rational for optimal remyelinat-
ing intervention times. In this way we tried to answer the follow-
ing questions: (i) Is promoting remyelination a beneficial strategy?
And, if so, (ii) does the success of promoting remyelination depend
on the localization of the lesion? (iii) Does the time of intervention/
remyelination affect the course of the disease?
In order to answer these questions, we needed to isolate the
demyelinating events from other MS hallmarks, an attempt which
was possible only by performing a translational study in animal
models. We choose to use (i) the cuprizone model of general
de- and remyelination to determine the consequences of massive
myelin loss and re-growth and (ii) the lysolecithin model of focal
demyelination which allowed us to target locally restricted white
or gray matter lesions. We combined electrophysiology in vivo
with behavioral assays in freely behaving animals to investigate
the thalamocortical system which, besides being the ‘‘hot spot”
for gray matter lesions occurring in MS patients, has the advantage
of being a highly interconnected network featuring an extensive
white fiber tract (the internal capsule).2. Materials and methods
2.1. Animals and experimental design
All animal work was performed in accordance with the
2010/63/EU of the European Parliament and of the Council of 22
September 2010 and has been approved by the local authorities
(Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-
Westfalen; approval ID: 87-51.04.2010.A331). All efforts were
made to minimize the number of animals used and to avoid their
stress and suffering strictly following the ARRIVE guidelines
(Kilkenny et al., 2010). C57BL6 mice were used for all the experi-
ments and were singly caged, kept in a 12-h light/dark cycle, and
food and water were available ad libitum.2.1.1. Cuprizone treatment
C57BL6 mice were used for all experiments. The animals were
2–3 months old at the beginning of the experiments. Experimental
toxic demyelination was induced by feeding mice a diet containing
0.2% cuprizone (bis-cyclohexanone oxaldihydrazone, Sigma-
Aldrich Inc., Hamburg, Germany) mixed into a ground standard
rodent chow (Skripuletz et al., 2011). The cuprizone diet was main-
tained for 5–6 weeks. A second group, matched for age and sex,
served as control. Interruption of cuprizone administration favors
spontaneous remyelination (Skripuletz et al., 2008), therefore we
tested two other groups, 7 and 25 days after re-introduction of nor-
mal food (7-day remyelination and 25-day remyelination in the
text). In order to assess long term effects, an additional group of
animals was tested 45 days after stopping the treatment.
2.1.2. Lysolecithin injections
Anesthesia was induced with isoflurane (3% in O2; Abbot GmbH
& Co. KG, Wiesbaden, Germany), maintained with i.p. injection of
pentobarbital (50 mg/kg, Narcoren, Merial GmbH, Germany), and
additional doses were given if necessary (10–15% of the initial
dose). All pressure points were covered with 2% xylocaine gel
(Astra Zeneca GmbH, Wedel, Germany) and tissue to be incised
was injected with 2% xylocaine solution. Corneas were protected
with a dexpanthenol-containing gel (Bepanthen, Bayer,
Leverkusen, Germany). When animals were already anesthetized,
before beginning with the surgery, they received an additional
injection of carprofen (Rymadil, 5 mg/kg) in order to relieve post-
operatory pain. The head was mounted in a stereotaxic apparatus
(ASI Instruments, Inc., Warren, MI, USA) via ear bars, and the levels
of bregma and lambda were equalized. Craniotomies were per-
formed unilaterally (left hemisphere), thus one hemisphere served
as control. The dura mater was removed and then, by means of a
Hamilton syringe, lysolecithin (2 ll; at a speed of 10 nl/s) was
injected either in layer 4 of the primary auditory cortex (A1):
anteroposterior, 2.18 mm; lateral, 4.2 mm from bregma; and
dorsoventral, 1 mm from the brain surface; or in the internal
capsule (IC): anteroposterior, 0.94 mm; lateral, 2.10 mm;
dorsoventral, 2.5 mm (Paxinos and Franklin, 2001). The health
status of the animals, e.g. healing of the cranial wound and
exploratory activity, was checked daily for 7 days after surgery.
Then only after full recovery, animals were tested at 7 days after
lysolecithin injection when the demyelination effect was maximal
and then at 14 and 28 days to test for remyelination (Hall, 1972;
Pavelko et al., 1998). Animals matched for age, gender and
experimental time point were injected with vehicle solution and
served as controls. All injection sites/locations were verified by his-
tochemical staining after the recordings.
2.2. Tissue preparation and immunohistochemistry
Immunohistochemistry was performed on a group of six ani-
mals for each time point for the general demyelination and on a
group of three animals for the focal demyelination model. Briefly,
mice were deeply anesthetized using Foren (isofluran, 1-chloro-
2,2,2 trifluoroethyldifluoromethylether; 5% in O2) and then
perfused with 4% paraformaldehyde (PFA) in phosphate buffer
via the left cardiac ventricle as previously described (Skripuletz
et al., 2008). Brains were removed, postfixed in 4% PFA and paraffin
embedded. For light microscopy, 7-lm serial paraffin sections
were cut and dried at 37 C overnight, as described before
(Skripuletz et al., 2013). Paraffin embedded sections were de-
waxed, rehydrated, and microwaved for 5 min in 10 mM citrate
buffer (pH 6.0). Sections were quenched with H2O2, blocked for
1 h in phosphate-buffered solution (PBS) containing 3% normal
goat serum, 0.1% Triton X-100, and then incubated overnight with
the primary antibody. The following primary antibodies were
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otec) and for astrocytes glial fibrillary acidic protein (GFAP; mouse
IgG1, 1:200, Millipore). After washing, sections were further incu-
bated with biotinylated anti-mouse IgG (heavy and light chain)
secondary antibodies (1:500, Vector Laboratories) for 1 h followed
by peroxidase-coupled avidin–biotin complex (ABC Kit, Vector
Laboratories). Reactivity was visualized with diamino-3,30-
benzidine (Vector Laboratories). For cell staining, slides were coun-
terstained using Mayer’s hemalum solution (Merck). The extent of
myelination and astrogliosis was subsequently analyzed by light
microscopy (Olympus BX61). In particular, myelin protein-
stained sections for PLP were scored using a light microscope
(Leica). Scoring of demyelination was performed by three blinded
observers, using a scale of 0 (complete lack of myelin) to 4 (normal
myelin) (Skripuletz et al., 2008).
Tissue integrity and cellular infiltrates were characterized in
paraffin-embedded (Skripuletz et al., 2008) and cryopreserved
sections (Göbel et al., 2010) using the following marker: activated
microglia were detected using Iba-1 (Wako), GFAP (Sigma) was
used as marker for astrocytes, CD3 for T cells. After washing, sec-
tions were incubated with the respective secondary antibody for
1 h, followed by peroxidase-coupled ABC Kit (Vector Laboratories,
Burlingame, UK) or directly mounted with Mowiol (Calbiochem,
San Diego, CA, USA) containing DAPI (Invitrogen, Carlsbad, CA). Cell
counting was performed for the following marker: GFAP, Iba-1, and
CD3. Immunopositive cells in the auditory cortex and in the inter-
nal capsule were counted. Values are presented as number of cells
per mm2.2.3. Flow cytometry
Flow cytometric analysis of murine peripheral leukocytes was
performed as previously described (Ruck et al., 2013). Cells were
analyzed on a Gallios Flow Cytometer (Beckman Coulter, Krefeld,
Germany). Antibody concentrations were carefully titrated prior
to experiments. For flow cytometric evaluation of CNS-invading
cells, mice were perfused transcardially with PBS to diminish con-
tamination by leukocytes located within the blood vessels. CNS tis-
sue was dissociated mechanically; followed by an enzymatic
digestion with collagenase CLS2 (Worthington, Lakewood, NJ,
USA) and DNAse (Sigma Aldrich, Munich, Germany) for 45 min at
37 C. After two washing steps, the cell suspension was transferred
to a 30%/50% Percoll (Amersham, Piscataway, NJ, USA) density gra-
dient. After centrifugation (2500 rpm, 30 min, 20 C) mononuclear
cells were isolated from the interface of the gradient, counted by a
Casy Model TT cell counter (Innovatis AG, Reutlingen, Germany)
and stained with appropriate antibodies. The following primary
anti-mouse antibodies were used for flow cytometry: the respec-
tive isotype controls and CD11b-PerCP-Cy5.5 (clone M1/70) were
purchased from BD Biosciences (Heidelberg, Germany); CD3-
Brilliant Violet 510 (clone 17A2), CD4-Pacific Blue (clone GK1.5),
CD8a-AF700 (clone 53-6.7), CD11b-APC (clone M1/70), CD11c-
APC (clone N418), CD25-FITC (clone PC61), CD45-FITC (clone 30-
F11), CD69-PE (clone H1.2F3), CD86-PE-Cy7 (clone GL-1), F4/80
(clone BM8) were purchased from Biolegend (Fell, Germany);
CD40-PE (clone 1C10), MHC class II (I-A/I-E)-APC-eFluor780 (clone
M5/114.15.2) were purchased from eBioscience (San Diego, CA,
USA).2.4. Immunological analysis
Cervical lymph node cells were isolated either from control
mice or from cuprizone-treated mice. Cells were stimulated with
anti-CD3 (2 lg/ml) and anti-CD28 (1 lg/ml) antibodies. IFNc and
IL-17A levels were assessed by enzyme-linked immunosorbentassay (ELISA, Ready-SET-Go! ELISA kit; eBioscience, Frankfurt,
Germany).
For evaluation of cell proliferation, the amount of ATP in the
supernatant after cell lysis was assessed as an indicator of cell pro-
liferation using an ATPlite luminescene ATP detection assay system
(PerkinElmer, Waltham, USA) according to the manufacturer’s
instructions. Luminescence was measured on an Infinite 200 PRO
multimode microplate reader (Tecan, Switzerland).2.5. Electrophysiology – in vivo recordings
2.5.1. Electrode implantation
For recording of spontaneous and auditory stimulus-induced
unit activities in freely behaving mice, microwire arrays (one array,
eight electrodes and one reference/array per brain region;
Stablohm 650; California Fine Wire, USA) were implanted under
stereotaxic control (David Kopf Instruments, USA). The tip of each
wire was gold plated by passing a cathodal current of 1 lA while
wires were submerged in a gold solution to reduce the impedance
to a range of 150–300 kO. Under deep pentobarbital anesthesia
(50 mg/kg i.p.), supplemented by subcutaneous injection of carpro-
fen (Rimadyl; 5 mg/kg), electrodes were implanted in the left
hemisphere using the following stereotaxic coordinates (Paxinos
and Franklin, 2001): A1 layer 4: anteroposterior 2.18 mm, lateral
4.2 mm from bregma, and dorsoventral 1 mm from the brain
surface. Electrodes were fixed with dental cement (Pulpdent-
GlassLute, Corporation Watertown, MA; USA). An additional
ground electrode was positioned close to the midline over the cere-
bellar region (5.8/0.5 mm from bregma) in the right hemisphere.
The health status of the animals and their recovery, e.g. healing
of the cranial wound and exploratory activity, was checked daily
for 7 days after surgery. At the end of the experiments, animals
were killed by an overdose of pentobarbital (100 mg/kg, i.p), loca-
tion of the electrode sites were marked by small electrolytic lesions
(2.5 mA anodal current for 2 s) and brains were rapidly removed
and fixed in 4% phosphate-buffered formaldehyde, pH 7.4.
Electrode positions were identified in 50 lM cresyl violet-
counterstained coronal brain sections (Fig. 2A) and anatomically
located (Supplementary Fig. 2A).2.5.2. In vivo electrophysiological recordings
After 7–10 days of surgical recovery, recordings of unit activi-
ties were performed. In cuprizone-treated mice, recordings were
performed at three different time points: after full demyelination
(cuprizone in the text), and during early (day 7) and late (day
25) remyelination (Franco-Pons et al., 2007; Skripuletz et al.,
2011). Focal demyelination was induced by local lysolecithin injec-
tion in A1 and IC. First recordings from focally demyelinated mice
were performed 7 days after lysolecithin injection (this group is
referred to as day 7 in the text). Next, neuronal activity was
recorded during the remyelinating phase (day 14) and following
complete remyelination (day 28) (Hall, 1972; Pavelko et al.,
1998). Recordings obtained in the same mice prior to lysolecithin
injection (day 1) served as control. The recordings were performed
before, during, and after the presentation of an auditory stimulus
consisting of a sequence with six repetitions of either low- or
high-frequency tones (2.5 kHz and 10 kHz at 85 dB, respectively;
Fig. 2A). Neuronal activity was recorded with a Multichannel
Amplifier System (Alpha Omega, Israel) and stored on a personal
computer (IBM). Unit activities were bandpass filtered at 9 kHz,
at a sampling rate of 40 kHz. Spikes of individual neurons were
sorted by time–amplitude window discrimination and principal
component analysis (Offline Sorter, Plexon Inc., Dallas, TX, USA)
and verified through quantification of cluster separation, as
described before (Narayanan et al., 2011).
 Control
 Cuprizone 
 Remyelination 7 days
 Remyelination 25 days
0
0.2
0.4
0.6
0.8
1
1.2
R
el
at
iv
e 
pr
ol
ife
ra
tio
n
J
0
2
4
6
8
10
IF
N
 p
ro
du
ct
io
n
(n
g/
m
l)
K
0
1
2
3
IL
17
 p
ro
du
ct
io
n
(p
g/
m
l)
L
[O
D
]/[
O
D
]k
id
ne
y
0
0.10
Spinal 
cord
Brain
0.05
M
Po
si
tiv
e 
C
N
S 
ce
lls
 (%
)
0
20
40
60
80
100
D FE
G
0
5
10
15
20
25
CD4
CD25
CD4
CD69
CD8
CD25
CD8
CD69P
os
iti
ve
 c
er
vi
ca
l L
N
 c
el
ls
 (%
)
CD4
CD25
CD4
CD69
CD8
CD25
CD8
CD69
H I
CD4
CD25
CD4
CD69
CD8
CD25
CD8
CD69
0
20
40
C
C
N
S 
im
m
un
e 
ce
lls
(a
bs
ol
ut
e 
nu
m
be
rs
)
CD4 CD8 CD11b
0
20000
40000
60000
80000 Control
Cuprizone
EAE
B
CNPase
HE
SMI31
MGN A1
MGN A1
MGN A1
MGN
MGN
MGN
A1
A1
A1
A
m
ye
lin
m
ye
lin
as
tro
cy
te
s
m
ye
lin
as
tro
cy
te
s
A1
M
G
N
Control Cuprizone
(6 weeks)
Remyelination
(7 days)
Remyelination
(25 days)
Fig. 1. Cuprizone-induced demyelination is not accompanied by adaptive immune system activation or BBB breakdown. (A) In cuprizone-treated animals, myelin loss,
quantified using PLP as marker, was found in the auditory cortex (A1; column 2, rows 1–2) and in the medial geniculate nucleus (MGN; row 5) compared with control. During
demyelination, marked time-dependent astrogliosis (GFAP marker) was observed (row 3). (B) Staining with HE, CNPase (adult oligodendrocytes marker), and SMI31 (axonal
marker) in acute brain slices containing A1 and MGN. (C) Flow cytometric evaluation of CNS CD4+, CD8+, and CD11b+ cells revealed no differences between controls and
cuprizone-treated mice compared to typical EAE-observed values. (D–F) Unaltered activation of CD25 and CD69 markers was observed in CNS-present CD4+ and CD8+ T
lymphocytes in cuprizone-treated mice (D), 7 (E) and 25 (F) days after remyelination when compared to age- and gender-matched controls (black bars). (G–I) CD4+ and
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Basal and stimulus evoked activity, as well as z-scores of sorted
neurons were analyzed by a customized MATLAB routine (The
MathWorks). For all analyses except firing-latencies, the time axis
of experimental sessions was divided into 1 s bins to calculate
firing-rates and z-scores. Firing rates have been calculated as
spike-count per second. Values obtained during the first 60 s ofan experimental session were defined as baseline activity for every
single neuron. Individual firing rates were z-scored to their respec-
tive mean baseline activity. Neurons were defined as ‘‘responsive”
neurons if at least one bin showed z-scoreP 1.96 in response to
stimulus presentation. For analysis of firing-latencies, the time axis
of experimental sessions was divided into 0.01 s bins. The latency
was defined as the time between the stimulus presentation and the
108 M. Cerina et al. / Brain, Behavior, and Immunity 59 (2017) 103–117neuronal response in A1. Analysis was performed by dividing the
time axis into 0.01-s bins and by calculating the overall number
of spike occurring per bin. Thereafter, the time difference between
the time bin of the stimulus onset and the first following time bin
showingmore than one AP (user-defined threshold) was evaluated.
In the text, n is given as number of neurons/number of animals
recorded.
2.6. Behavioral test
After termination of cuprizone treatment and 25 days after
remyelination, mice underwent a modified fear-conditioning pro-
tocol to evaluate their ability to discriminate auditory stimulus fre-
quencies: mice (5 per group) were adapted twice to the fear-
conditioning apparatus with six neutral tones (unconditioned
stimulus CS, 2.5 kHz tone, 85 dB, 10-s duration). On the next
day, fear conditioning was performed through two trials of three
presentations of the conditioned stimulus (CS+, 10 kHz tone,
85 dB, 9-s duration) paired with an unconditioned stimulus
(scrambled foot shock of 0.4 mA, 1-s duration). After 24 h, freezing,
namely the percentage of immobility of the animal in response to
the conditioned stimulus which is a typical fear-conditioning-
related behavior, was taken as readout. Another batch of experi-
ments was performed on the same experimental groups inverting
the protocol, with CS+, 2.5 kHz as the conditioning tone and CS
10 kHz as adaptation tone.
The same behavioral paradigm was used in another battery of
experiments where animals were injected with lysolecithin either
in A1 or IC (6–7 animals per group). Animals were tested using the
protocol with 10 kHz as conditioning tone at different time points:
7, 14 and 28 days after lysolecithin injection. Two additional
groups were injected with saline either in IC or in A1 and tested
7 days after injection. These animals were considered as control
as we observed no serious histopathological damage (see para-
graph 3.5) and no behavioral changes at this critical time point
after lysolecithin injection.
2.7. Statistics and data analysis
All results are presented as mean ± SEM. Statistical significance
was analyzed using One-way ANOVA, factorial ANOVA or mixed
designs ANOVAs when both repeated measures and multivariate
analysis needed to be performed. Analyses were followed by Bon-
ferroni post hoc tests or by the Least Significant Difference test
(LSD) for multiple or pairwise comparisons as specified in the text.
For all analyses Statistica (Statsoft, USA), SPSS (IBM Analytics) and
Graphpad (Prism 5, GraphPad) were used. Graphs and figures were
prepared using Origin, GraphPad, and Coreldraw.3. Results
3.1. Demyelination induced by cuprizone treatment is not associated
with inflammation mediated by the adaptive immune system
By choosing the cuprizone model for general demyelination, we
aimed to answer our question concerning the consequences of a
general and massive loss of myelin in the central nervous system.
Treatment with the copper chelator cuprizone is an established
model of general demyelination preferentially targeting mature
oligodendrocytes (Matsushima and Morell, 2001; Skripuletz
et al., 2011) and inducing demyelination in mice after 5–6 weeks
of administration. Staining with the myelin-specific proteolipid
protein (PLP) allowed quantification of the myelin content which
was reduced in A1 (myelin score: control, 4; cuprizone,
0.67 ± 0.27; p < 0.01; Fig. 1A and Supplementary Fig. 1C) as wellas in MGN (Fig. 1A) which are parts of a reciprocally connected net-
work including axons and oligodendrocytes (Fig. 1B). The mecha-
nisms underlying cuprizone-induced demyelination, which are
not entirely known (Skripuletz et al., 2011), are accompanied by
astrocytosis and microglia activation (Fig. 1A and Supplementary
Fig. 1A, B). Moreover, no indication of cell infiltration was observed
following demyelination. This was especially evident when we
compared absolute CD8+, CD4+ and CD11b cell numbers obtained
by experimental encephalomyelitis animal models to our experi-
mental groups and controls (Fig. 1C and Supplementary Fig. 1B).
Further we analyzed the contribution of different CD4+ and CD8+
population subtypes (CD25 and CD69) to the overall small number
of immune cells that we detected in our experimental groups. No
signs of inflammation or presence of activation markers of the
adaptive immune system were observed following cuprizone
treatment compared to respective controls. Termination of the
treatment allowed spontaneous remyelination and no signs of
inflammation were visible during the early and late phases of
remyelination (7 and 25 days, respectively; Fig. 1D–I). In detail,
analysis of the effect of time, i.e. the differences between de- and
remyelination phases, was not significant for the CD4+ and CD8+
subpopulations in the brain (factorial ANOVA, main effect of time:
F(4,26) = 2.06, p = 0.115 and F(4,26) = 1.55, p = 0.216, respectively).
The analysis of the time effect in immune cell subpopulations iso-
lated from lymphnodes showed no changes during de- and
remyelination for the markers CD8/CD25 and CD69 (F(4,26) = 0.33,
p = 0.855) but we observed an effect for CD69 expression on
CD4+ T cells (F(4,26) = 3.54, p < 0.05). This isolated effect could be
attributed to differences in the respective control groups and was
considered to not be biologically meaningful. Furthermore, no indi-
cations of peripheral inflammation (Fig. 1J–L) or blood–brain bar-
rier (BBB) damage were observed (Fig. 1M). Taken together, this
approach provided a feasible basis to study the functional conse-
quences mediated by demyelination only, independently from
major inflammatory influences.
3.2. General demyelination permanently alters the auditory neuronal
network functionality in vivo
After havingvalidatedourmodel, thenext stepwas to investigate
the functional consequences of general demyelination by perform-
ing in vivo electrophysiology in freely behaving animals. We
recorded single-unit activity in individualmice fromA1 in a longitu-
dinal approach under control conditions, the time of maximal
demyelination, and during different phases of remyelination (7, 25
and 45 days in the same animal). Recording electrodes were
implanted in layer 4 of A1 (Fig. 2A) in a tonotopic position where
neurons are known to respond to frequencies higher than 8 kHz
(Hackett et al., 2011;Musacchia et al., 2014). The animalswere then
exposed to tones of two different frequencies (2.5 and 10 kHz) and
neuronal activity was recorded and analyzed (Supplementary
Fig. 2A–D). Typical rate histograms showed auditory stimulus-
inducedpeaks of activity onabackgroundof basal activity. In control
animals, a sharp increase in activitywas evoked by the presentation
of the higher frequency stimulus (10 kHz; Fig. 2B, black traces). In
the cuprizone-treated animals, thebackgroundactivitywasdramat-
ically reduced with no clear response to auditory stimuli, indicating
heavily impaired neuronal network functioning. Interestingly,
allowing remyelination in the same animals, during both the early
and late phases, partially restored basal activity (Fig. 2B, yellow
and magenta traces, respectively) although no clear discrimination
between tone frequencieswas detectable, namely therewere nodif-
ferences in responsiveness to 2.5 and10 kHz.Next,weanalyzedonly
the activity of the neurons responding to the stimulus in order to dif-
ferentiate theirs from the background activity. We achieved that by
including in the analysis only neurons showing a significant positive
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Fig. 3. Altered discrimination responses and freezing behavior as consequence of
demyelination. (A) Control animals showed a high percentage of freezing behavior
when exposed to the conditioning stimulus (10 kHz) compared with exposure to
the unconditioned stimulus (2.5 kHz; ***p < 0.001; n = 5). (B–C) After cuprizone
treatment (B) and in the late remyelination phase (C) animals show no differences
in the freezing percentage upon presentation of either 2.5- or 10-kHz stimuli. (D–F)
Using 10 kHz as unconditioned stimulus and 2.5 kHz as conditioned stimulus,
control animals show high freezing in response to the 2.5-kHz but not to the 10-kHz
stimulus (D; ***p < 0.001) while there is no difference in the cuprizone-treated (E)
and the remyelinated group (F).
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the neurons whose significant response (p 6 0.05) was 1.96 folds
higher than the baseline (z-scoreP 1.96 to baseline, p 6 0.05; indi-
cated in Fig. 2 by horizontal dashed lines). We observed a strong
increase in neuronal activity in response to high frequencies
(10 kHz; Fig. 2C, black traces and Supplementary Fig. 2B) proving
the response specificity and discrimination properties of A1 neu-
rons. Moreover, after cuprizone treatment, the neuronal ability to
respond to auditory stimuli was largely reduced at either tested fre-
quency (Fig. 2C, blue traces and Supplementary Fig. 2C). The z-score
analysis further indicated a recovery of auditory stimulus-induced
activity during all phases of remyelination as theneurons responded
to the stimulus. However, no differentiation between stimulus fre-
quencies (2.5 and10 kHz)wasdetected (Fig. 2C, yellowandmagenta
traces, Supplementary Figs. 2D and 3A) suggesting that the ability of
the network to discriminate between the two frequencies was lost.
These changeswere further characterized by stimulus-related firing
rate analysis showing a main effect of time (mixed design ANOVA,
F(1,171) = 5.44, p = 0.021), and thus differences between de- and
remyeliantion phases. An effect of frequency (F(2,342) = 73.91,
p < 0.001) was also observed interacting with the time domain
(F(4,342) = 4.91, p = 0.002), thereby indicating that changes in the
neuronal response during the presentation of the different frequen-
cies were influenced by the different de- and remyelination phases
(Fig. 2D). Interestingly, the alterations observed at 25 days of
remyelination, persisted also 45 days after remyelination indicating
that a prolonged remyelination period does not rescue altered neu-
ronal responses (Supplementary Fig. 3A).
Another parameter often shown to be affected by demyelina-
tion is the response latency (Hamada and Kole, 2015; Kim et al.,
2013), defined as the time between the presentation of the stimu-
lus and the activation of the corresponding interconnected area
which, in our model is A1. In line with the literature, in our study,
the response latencies to auditory stimuli for cortical responsive
neurons were significantly longer after demyelination (control,
39.04 ± 10.46 ms; cuprizone, 185.58 ± 21.96 ms; p < 0.001 vs.
respective control) indicating a clear impairment in the ability of
the network to convey the information. Again, as shown for the
neuronal amplitude, allowing remyelination only partially recov-
ered such impairment during the early (control for day 7,
41.48 ± 5.81 ms; 7-day remyelination, 113.93 ± 21.9 ms) and late
phase of remyelination (control for day 25, 40.0 ± 4.41 ms;
25-day remyelination, 100.52 ± 19.59 ms; one-way ANOVA; effect
of time: F(2,102) = 46.65, p < 0.001; pairwise comparisons: 7- and
25-day remyelination vs. respective controls, p < 0.05; 7-day
remyelination vs. cuprizone, p < 0.05; 25-day remyelination vs.
cuprizone, p < 0.01; Fig. 2E and Supplementary Fig. 3B).
3.3. De- and remyelination alter auditory conditioned behavioral
responses in freely behaving animals
To assess the existence of a behavioral correlate between the
permanent changes of neuronal activity observed after demyelina-
tion and during remyelination, we tested the ability of mice to dis-
criminate different tones in a discriminative auditory Pavlovian
conditioning paradigm with freezing as the behavioral readout
(Daldrup et al., 2015; Narayanan et al., 2011). Animals were
adapted to a 2.5 kHz stimulus and then conditioned with the
10 kHz stimulus coupled to a mild electrical foot shock. Control
animals were successfully conditioned and showed significantly
higher freezing upon presentation of the conditioned auditory
stimulus (10 kHz; control freezing, 63.27 ± 2.34%; Fig. 3A; mixed
design ANOVA, effect of frequency: F(1,12) = 40.36, p < 0.001) com-
pared with the freezing evoked by the presentation of the non-
conditioned stimulus (2.5 kHz; control freezing, 20.5 ± 7.35%;
p < 0.001 vs. 10 kHz; Fig. 3A). The cuprizone-treated mice showedhigh freezing in response to both stimuli (freezing: 2.5 kHz,
75.84 ± 3.78%; 10 kHz, 84.52 ± 4.11%; p = 0.127; Fig. 3B) and the
same effect was observed after 25 days of remyelination (freezing:
2.5 kHz, 79.36 ± 4.18%; 10 kHz, 86.25 ± 1.35%; p = 0.218; Fig. 3C)
suggesting impaired frequency discrimination and indicating that
the regrowth of myelin is insufficient to rescue the phenotype
(mixed design ANOVA, main effect of time: F(2,12) = 46.5, p < 0.001
and interaction between time and frequency: F(2,12) = 15.5,
p < 0.001; pairwise comparison shows no differences between
cuprizone-treated animals and 25-day remyelination: p = 0.65 for
2.5 kHz and p = 0.67 for 10 kHz). Very similar results were obtained
when the paradigm parameters were inverted, with 2.5 kHz as
conditioned stimulus (control freezing: 2.5 kHz, 83.45 ± 3.52%;
10 kHz, 19.38 ± 3.1%; cuprizone freezing: 2.5 kHz, 56.73 ± 11.39%;
10 kHz, 53.51 ± 2.71%; 25-day remyelination freezing: 2.5 kHz,
69.93 ± 9.96%; 10 kHz, 77.36 ± 3.49%; mixed design ANOVA, main
effect of time: F(2,12) = 7.82, p = 0.007 and interaction between time
and frequency: F(2,12) = 28.59, p < 0.001; pairwise comparison:
p < 0.001 for controls; Fig. 3D–F). Moreover, additional control
experiments in which randomly presented high- and low-
frequency stimuli of different durations were performed to exclude
any learning or pre-existing deficits before behavioral testing
(Supplementary Fig. 4A–C).3.4. Distinct functional consequences of de- and remyelination after
lesions in white and cortical gray matter
Having demonstrated that general demyelination heavily
impairs neuronal activity in the thalamocortical system and
110 M. Cerina et al. / Brain, Behavior, and Immunity 59 (2017) 103–117thereby behavior in vivo, our next step was to assess whether focal
demyelination of white- or gray matter of the auditory pathway
differently impacted network function in a region-specific manner.
This approach takes advantage of the ability to mimic typical
region-specific pathophysiological lesions observed in human dis-
eases (Muto et al., 2015; Sahin et al., 2015). The more localized
gray-matter demyelination events (in comparison to cuprizone-
induced events) induced by focal injection of lysolecithin in A1
reduced the response of the A1 neurons to auditory stimuli already
at 7 days post injection (z-score 6 1.96 to baseline, p < 0.05; black
traces vs. cyan traces; Fig. 4A, B) with significant differences in
the firing rate for every presented frequency and in comparison
to the other time points (repeated measures ANOVA, effect of fre-
quency: F(2,38) = 33,39, p < 0.001; pairwise comparison for 10 kHz:
7-day lysolecithin vs. 7-day control: p = 0.015; 7-day lysolecithin
vs. 14-day lysolecithin: p = 0.03 and 7-day lysolecithin vs. 28-day
lysolecithin: p = 0.02; Supplementary Fig. 5A, B). During remyeli-
nation, responses to auditory stimuli were partially restored in
A1, while the ability to discriminate different tone frequencies
seemed to be permanently lost, as indicated by the z-score and
the stimulus-related firing rate analyses at 14 and 28 days post
injection (lysolecithin cyan traces vs. control black traces; repeated
measures ANOVA, interaction between frequency and time:
F(6,114) = 6.97, 10 kHz vs. 2.5 kHz at 14-day lysolecithin vs 28-day
lysolecithin, p = 0.23; Fig. 4A, B and Supplementary Fig. 5A, B).
The cortical response latency to auditory stimuli increased 7 days
after lysolecithin injection in A1 compared to controls
(151.82 ± 16.53 ms vs. 32.33 ± 7.52 ms, respectively; repeated
measures ANOVA, F(3,36) = 21, p < 0.001; Bonferroni post hoc test:
p < 0.001; Fig. 4E) and was partially restored in the following
weeks of remyelination, although not reaching control values
(14-day, 85 ± 12 ms; 28-day, 89 ± 12.88 ms; Fig. 4E). In contrast,
the focal demyelination of the white matter, specifically in the
internal capsule (IC), induced only a transient decrease in A1
neuron responses and relative firing rate upon presentation of all
frequencies (7-day, black and purple traces and bars; 7-day base-
line vs. 2.5 kHz vs. 10 kHz; Fig. 4C, D and Supplementary Fig. 5C,
D) which increased 14 and 28 days post injection (repeated mea-
sures ANOVA, effect of frequency: F(2,54) = 27.44, p < 0.001 and
interaction between frequency and time: F(6,162) = 6.41, p = 0.001;
Supplementary Fig. 5C, D) when it reached control (pre-injection-
like) values. Accordingly, the latency in A1 was also significantly
increased by the demyelination of the IC (control, 38.4 ± 3.20 ms;
7-day lysolecithin IC, 103.24 ± 12.01 ms; repeated measures
ANOVA, F(3,69) = 27.4, p < 0.001; Bonferroni post hoc test,
p < 0.001 vs. 1-day; Fig. 4F) and control conditions were almost
completely restored in the early (14-day, 61.16 ± 2.77 ms;
Fig. 4F) and late phase of remyelination (28-day, 38.91 ± 2.79 ms;
p = 1 vs. 1-day; Fig. 4F).
3.5. Lysolecithin targets myelin and triggers microglia activation
Upon lysolecithin injections, loss and restoration of myelin
were clearly observed in acute brain slices stained for the myelin
proteolipid protein (PLP) in A1: 7 days after lysolecithin injection,
the myelin score decreased (0.33 ± 0.27) compared to control
(myelin score, 4) and it increased 28 days after injection even
though not reaching control-like values (2.66 ± 0.27; Fig. 5A, first
row). Remyelination of white matter lesions was much more effi-
cient than in gray matter lesions: in IC, the myelin score signifi-
cantly decreased 7 days after lysolecithin injection (1 ± 0.47;
p < 0.05 vs. control) and finally reached control values 28 days
post-injection (3.67 ± 0.27; Fig 5A, third row). In accordance to pre-
vious evidence (Jeffery and Blakemore, 1995; Pourabdolhossein
et al., 2014), following lysolecithin injection (7 and 14 days after
injection), astrocytosis and microglia activation were observedboth in A1 and IC as indicated by increased signal for the GFAP
(astrocytosis, Fig. 5A, second and fourth row and Fig. 5B) and the
Iba1 markers (microglia, Fig. 5B). Of note, weak expression of
Iba1 was detected also in the control A1 and IC but it was resting
microglia. Indeed, activated microglia is characterized by a differ-
ent morphology: an amoeboid shape rather than spherical one
(Döring et al., 2015; Hall, 1972), as shown in the insets in
Fig. 5Ba–e. No signals for the CD3 marker were observed in A1
(data not shown) and very few cells were detected in IC (Fig. 5B).
Twenty-eight days after lysolecithin injection, less microglia acti-
vation and astrocytosis were observed compared to the previous
days (Fig. 5A and B).3.6. Auditory discrimination abilities are fully restored after
remyelination of a white but not a gray matter lesion
In the following, electrophysiological and immunohistological
data obtained from focally demyelinated animals were completed
by in vivo testing. Animals were injected with lysolecithin either in
A1 or in IC and tested with the Pavlovian conditioning paradigm for
auditory discrimination (see paragraph 2.6) at different time
points. Animals were tested 7 days after saline injection and 7,
14 and 28 days after lysolecithin injection. Saline injection, both
in A1 and IC did not affect discrimination of auditory stimuli as ani-
mals showed significantly higher freezing in response to the condi-
tioned stimulus at 10 kHz (76.38 ± 2.91% and 57.4 ± 7.98%
respectively), compared to the non-conditioned stimulus at
2.5 kHz (mixed design ANOVA, A1 effect of frequency,
F(1,46) = 30.29, p < 0.001; IC effect of frequency, F(1,44) = 109.9,
p < 0.001; Fig. 6A and E). Very low levels of freezing were observed
7 days after lysolecithin injection both in A1 (2.5 kHz:
12.13 ± 3.49% and 10 kHz: 12.44 ± 2.63%, Fig. 6B) and IC (2.5 kHz:
12.86 ± 4.2% and 10 kHz: 17.78 ± 0.84%, Fig. 6F) with no significant
differences in respect to the presented frequency. Interestingly, in
line with the low activity and the lack of discrimination observed
with single unit analysis, animals showed low but similar freezing
in response to both frequencies 14 days after injection in A1
(2.5 kHz: 23.1 ± 6.96% and 10 kHz: 21.01 ± 6.01%, Fig. 6C). Freezing
was increased 28 days after injection in A1 although animals did
not distinguish between tones at the two frequencies tested
(2.5 kHz: 56.84 ± 2.52% and 10 kHz: 60.51 ± 2.97%, Fig. 6D). This
finding is in line with a restored activity but lack of frequency dis-
crimination observed in the single unit analysis. Indeed, a mixed
design ANOVA analysis revealed effect of time, i.e. of remyelination
for both 2.5 and 10 kHz frequencies with F(3,46) = 65.15 and
p < 0.001 (Post-hoc analysis: saline vs. 7 and 14 days, p < 0.001
and vs. 28 days, p < 0.01). In contrast, animals showed stimulus-
specific behavioral responses similar to those observed under con-
trol conditions 14 (2.5 kHz: 23.1 ± 3.33% and 10 kHz: 54.8 ± 3.17%,
mixed design ANOVA, effect of time, F(3,44) = 15.01, p < 0.001;
Fig. 6G) and 28 days (2.5 kHz: 17.98 ± 3.33% and 10 kHz:
67.88 ± 6.25%, p < 0.001; Fig. 6H) after injection of lysolecithin in
the IC. These data indicate recovery of frequency discrimination
properties probably mediated by remyelination of white matter
lesions.4. Discussion
When considering the numerous pathological hallmarks char-
acterizing neurodegenerative diseases such as MS, a recurrent
event is the loss of myelin (Compston and Coles, 2008; Meuth
et al., 2010). Demyelination may occur at early or late stages of
the disease and has severe and unpredictable consequences. Proper
myelin functioning and plasticity are important for learning new
motoric and cognitive tasks in both humans and rodents (Furst
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Fig. 4. Focal demyelination permanently affects gray but not white matter. (A–B) Z-score showing impaired neuronal response to 2.5- and 10-kHz stimuli (green insets)
7 days after lysolecithin injection in A1 (n = 31/8; B, cyan traces) compared with saline (n = 6/3; A, black traces) and day 1 (n = 20/8; B, cyan traces). The impairment persists
14 (n = 43/7) and 28 (n = 25/7) days post-injection (B, cyan traces). (C-D) Cortical response decreased 7 days after lysolecithin injection in the IC (D, purple traces; n = 46/9)
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M. Cerina et al. / Brain, Behavior, and Immunity 59 (2017) 103–117 111and Levine, 2015; McKenzie et al., 2014; Sahin et al., 2015). Serious
cognitive deficits may, therefore, follow demyelination, especially
when the damage affects gray matter structures such as cortex
and thalamus as occurring in MS pathophysiology (Chang et al.,
2012; Mandolesi et al., 2010; Xu et al., 2009). Here already in early
disease stages, lesions have been shown to be present additional tothe white matter plaques (Deppe et al., 2014, 2013). Considering
the recent focus on the thalamocortical system in MS (Calabrese
et al., 2015; Matas et al., 2010; Meuth et al., 2010), we aimed to
identify consequences of demyelination on neuronal function in
the auditory cortex following general and focal demyelination.
Subsequently, we examined the role of lesion location by studying
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white matter lesions and concomitantly tested whether the time
course of recovery may point to timing strategies of therapeutic
intervention. In fact, some previous studies showed that persistent
demyelination or remyelination occurring outside a certain time
window irreversibly promote axonal damage (Crawford et al.,
2009b; Goldschmidt et al., 2009). Accordingly, our overall results
show that both localization and timing of lesion appearance and
remyelination occurrence affect the length of the disease course
and thus call for different times of intervention.General demyelination following treatment with cuprizone,
was associated with loss of frequency-specificity of tone-induced
auditory responses and the inability to condition mice to specific
tone frequencies in behavioral testing. These changes were not
based on brain lymphocyte infiltration or inflammation, even
though some astrocytosis and microglial activation were found.
Thus, they might be attributed mainly to demyelinating events
heavily impairing the neuronal network. By removing cuprizone
from the mouse diet we allowed for spontaneous endogenous
remyelination (Crawford et al., 2009b; Matsushima and Morell,
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indicated that myelin was restored: in terms of quantity these val-
ues resembled the control values probably mediating the increasedneuronal activity that we observed at 7 and 25 days of remyelina-
tion in response to auditory stimuli. Previous studies reported that
remyelination mainly occurred after an acute exposure to cupri-
zone (not more than 6 weeks, Matsushima and Morell, 2001) while
myelin was not fully reconstituted after a longer exposure to this
toxicant (Crawford et al., 2009a; Matsushima and Morell, 2001).
It was also shown that already thirty days after removing cupri-
zone from the diet, myelin reached control-like values which
remained stable afterwards (Liebetanz and Merkler, 2006;
Matsushima and Morell, 2001; Sachs et al., 2014). In many cases,
these stable levels of myelin were associated with locomotor defi-
cits (Zhang et al., 2013) and most strikingly, in our study, these
alterations were very clearly reflected by the inability of mice to
discriminate between two-tone frequencies in a Pavlovian condi-
tioning paradigm: demyelinated mice could still hear the tone as
indicated by a responsive freezing behavior, but this appeared irre-
spectively of the frequency of the presented tone. Very similar
results were obtained at 25 days of remyelination demonstrating
that remyelination was insufficient to restore neuronal functional-
ity. Several mechanisms may underlie the partial rescue of the
demyelination phenotype: it is known that remyelination is part
of a rescue mechanism initiated to protect and regenerate the
white matter in the brain (Long and Corfas, 2014). Nevertheless,
when this happens after pathological attack, or too late after a
given insult, the myelin machinery is probably already seriously
compromised and such restoration cannot be fully achieved
(Crawford et al., 2009b; Grydeland et al., 2013; Rodgers et al.,
2013). In fact, following demyelination a number of consequent
events occur to alter both myelin and neurons (Hirrlinger and
Nave, 2014). Oligodendrocyte death due to lack of metabolic sup-
port which is normally provided by astrocytes affects neuronal sur-
vival and axonal functioning (Nave and Werner, 2014; Skripuletz
et al., 2013). The disappearance of myelin wraps around the axon
lead to an altered expression of some ion channels i.e. Nav1.2,
Nav1.8 and Kv7.3 channels, whose correct functionality is impor-
tant for maintaining cell excitability (Bouafia et al., 2013;
Crawford et al., 2009b; Hamada and Kole, 2015). Furthermore, it
may be very difficult to discriminate between purely neuron- or
oligodendrocyte-mediated mechanisms due to their highly inter-
dependent cross talk.
At the same time, our data highlighted the importance of timing
and location of lesions to allow remyelination accompanied by
amelioration of discrimination properties in the auditory cortex.
By pharmacologically targeting white or gray matter regions with
lysolecithin we considered the ‘‘regionality” factor. Lysolecithin is
known to induce oligodendrocyte death, astrocytosis and microglia
activation thereby leading to transient demyelination. The latter is
followed by spontaneous remyelination promoted by oligodendro-
cytes progenitors (OPCs) that can access the targeted area after the
compound is metabolized and the debris of old myelin removed by
macrophages (Hall, 1972; Pavelko et al., 1998). MS pathophysiol-
ogy is characterized by defined and local lesions in the thalamocor-
tical system rather than a diffused general demyelination
(Calabrese et al., 2015; Deppe et al., 2016; Minagar et al., 2013)
and, via local lysolecithin injections we aimed at mimicking this
pathological feature more accurately. The focal demyelination
decreased neuronal activity recorded in A1 upon auditory stimulus
presentation when lysolecithin was injected into A1 and IC in a
very similar way (Fig. 7C1 and D1). But, interestingly, during the
remyelination phase, we observed complete recovery of the sys-
tem, with regard to neuronal response, frequency discrimination
in vivo, 28 days after injection when solely the IC was targeted.
In contrast, no functional positive effect of remyelination was
observed for the discrimination abilities of the cortical neurons
when A1 was affected (Fig. 7C1 and C2). This outcome indicates
that the positive effect of spontaneous remyelination, which could
Fig. 7. Graphic summary of the effects of general and focal de- and remyelination in A1. (A) Schematic representation of a well-functioning auditory thalamocortical pathway,
as indicated by the green arrows and the positive sign (+), with intact myelin organization and physiological cortical single-unit response. Cuprizone-induced general (B1) and
focal demyelinated lesions induced by lysolecithin injection in A1 (gray matter; C1) or in IC (white matter; D1), dramatically decreased cortical neuronal response to any
stimulus (electrical or auditory one), as indicated by the dashed-red arrows and the negative sign (). General remyelination (B2) and cortical focal remyelination after A1
lysolecithin-induced lesion (C2) are accompanied by a restored neuronal activity but permanent loss of frequency-discrimination abilities in response to an auditory stimulus
(dashed green arrows and the sign (+/)). In contrast, the focal remyelination occurring after a lysolecithin-induced IC (white matter) lesion was associated with both
restored activity and discriminatory skills in A1 (green dashed arrows and the sign (+); D2). (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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et al., 2009b), was region- and time-specific. In fact, the phenotype
was rescued only after 28 days (and not at intermediate time
points), but this only happened when solely the white matter
was affected. Moreover, the gray matter lesion in A1 showed a
functional course similar to the cuprizone-treated animals eluci-
dating the importance of the spatiotemporal characteristics of
lesions. After all, general demyelination affected both white matter
integrity and gray matter functionality (Crawford et al., 2009b;
Hamada and Kole, 2015). Thus, not only local cortico-cortical
circuits were affected but also long-range connections to many
subcortical regions that could have contributed to the heavily
impaired cortical network function (Crawford et al., 2009b;
Tewarie et al., 2014a,b). Therefore, this would suggest a regulation
of neuronal function by axonal myelination or vice versa, thereby
supporting the concept of interaction between myelin turnover
and axonal activity (Yeung et al., 2014). In line with these findings,
the fine tuning of myelination processes, like the correct migration
of oligodendrocyte progenitor cells, was shown to be fundamental
for learning and consolidating new motor tasks (McKenzie et al.,
2014). Also learning new tasks and acquiring new skills simultane-ously promotes myelination itself and the maintenance of a func-
tioning myelin machinery (Sampaio-Baptista et al., 2013). In this
regard, the loss of myelin in the cuprizone model could mediate
the inability of the animals to discriminate between the tones
and their high percentage of freezing. In fact, the loss of myelin
would affect the directionality of the incoming stimulus as well
as cortico-cortical connections of the local auditory circuit of A1
which is involved in the fine tuning of different frequencies
(Groh et al., 2014; Hackett et al., 2011; Musacchia et al., 2014).
Therefore the behavioral changes observed even after remyelina-
tion suggest a persistent impairment of the neuronal network
deriving from an alteration of the cortico-cortical connection
and/or the activation of compensatory mechanisms, likely involv-
ing sub-cortical auditory-related regions (Groh et al., 2014)
thereby pointing to a dominant role played by gray matter regions
in general. This hypothesis is supported by the observed functional
consequences of white and gray matter lesions in lysolecithin-
injected animals. A remyelinated white matter lesion was
associated with functional restoration of auditory discrimination
capabilities in mice. On the contrary, gray matter lesions were
associated with permanent auditory frequency discrimination loss.
M. Cerina et al. / Brain, Behavior, and Immunity 59 (2017) 103–117 115Previous evidence has suggested a link between gray matter dam-
age and the onset of cognitive and motor deficits (Calabrese et al.,
2009; Gamboa et al., 2014; Tewarie et al., 2014a,b). Nevertheless,
the diagnosis, location and handling of white and/or gray matter
lesions and their functional consequences, are an ongoing issue
of debate (Parisi et al., 2014). In earlier days, white matter lesions
were considered the hallmark for diagnosis of MS in patients
(Hulst and Geurts, 2011) and were the earliest characteristics to
be clinically detected (Parisi et al., 2014) mainly because functional
deficits leading to consultation normally appear later in the disease
course or they were difficult to associate to it (Benedict et al.,
2004). In some cases, such association was so unlikely that physi-
cians talked about a cortical MS disease, a parallel disease mainly
characterized by functional cognitive and locomotor deficits
(Riccitelli et al., 2011; Zarei et al., 2003). Nowadays, gray matter
lesions are identified at early stages of the disease (Deppe et al.,
2016; Fleischer et al., 2016) due to more advanced technological
approaches. Moreover, besides damaged gray matter regions, epi-
sodes of atrophy and cortical thinning were observed so that they
are also considered as disease hallmarks (Calabrese et al., 2010;
Vercellino et al., 2005). Therefore a large number of functional con-
sequences of cortical damage have to be considered. Alterations of
the cortico-cortical connections and white/gray matter disruption
were associated with changes in neuronal clustering within the
cortex and were postulated to underlie altered neuronal excitabil-
ity in MS and Alzheimer’s patients, as well in animal models of
neurodegeneration, (Fleischer et al., 2016; Ghaffarian et al., 2016;
Markoullis et al., 2012; Sutor et al., 2000; Villain et al., 2010). In
our case, such reorganization would indeed have important conse-
quences given the strict topographic and tonotopic organization of
the neurons in A1 (Hackett et al., 2011; Musacchia et al., 2014).
Interestingly, fMRI studies in MS patients revealed hierarchical
alterations of cortex and interconnected subcortical regions which
were related to altered neuronal network functioning and cogni-
tive impairment (Gamboa et al., 2014; He et al., 2009; Sanfilipo
et al., 2006; Tewarie et al., 2014a,b) and, similar to rodents, cortical
structural alterations were associated with the onset of cognitive
and motor deficits (Nave and Werner, 2014; Zhou et al., 2013).
Despite advanced techniques for diagnosis, broad availability of
different drugs and new basic or clinical research aiming to
identify, distinguish and characterize the two types of lesions,
the reciprocal causality of the appearance of the white and gray
matter lesions (Bodini et al., 2016; De Stefano et al., 2003) and their
functional correlation (Bo et al., 2007) remain unclear. Assessing
whether a damaged cortex influences myelin functionality or if a
white matter lesion triggers the occurrence of gray matter damage
is challenging.5. Conclusion
In conclusion, it is important to consider the clinical implica-
tions and the translational potential of the findings we describe
herein. The evidence that a gray matter lesion exerts different
functional consequences compared to a white matter lesion is a
significant observation with profound implications for those
patients diagnosed with severe gray matter damage. The successful
recovery of function following remyelination of white matter
lesions might give important hints to the mechanisms of action
of novel treatment options for MS, such as anti-LINGO, an antibody
directed against the LINGO-1 protein which inhibits myelin syn-
thesis (Agúndez et al., 2015; Inoue et al., 2007; Rudick et al.,
2008). The first trial with patients affected by optic neuritis (ON)
was able to show a significant decrease of visual-evoked potential
latencies in the anti-LINGO1 group compared to the control group.
ON is mainly characterized by demyelination and this stronglysupports the conclusion that promoting remyelination seems to
be the right approach in cases of white matter damage (Biogen’s
anti-LINGO promises nerve repair, 2015; Mullard, 2016). More-
over, the insights of our study might help to select eligible patients,
who will benefit the most from these new therapies. We believe
that our approach can be used as a tool or a model providing a
conceptual framework to understand the mechanisms of action
of existing drugs, to assist new drug discovery and to develop
individualized diagnostic and therapeutic strategies based on the
characterization of lesions and the timing of intervention.
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